Lia DeGroot

As the year is near­ing a close, law­mak­ers are still chip­ping away at spend­ing bills and a long to-do list of health pol­i­cy pri­or­i­ties that

Pres­i­dent Joe Biden on Mon­day signed a wide-rang­ing ex­ec­u­tive or­der seek­ing to stream­line how the gov­ern­ment us­es and reg­u­lates ar­ti­fi­cial in­tel­li­gence, with some broad im­pli­ca­tions

As the le­gal land­scape for re­pro­duc­tive rights in the US re­mains in flux, De­moc­rats in the Sen­ate are call­ing on the Biden ad­min­is­tra­tion to re­quire

As CMS and phar­ma com­pa­nies pre­pare to hash out the first round of Medicare drug price ne­go­ti­a­tion pro­vi­sions of the In­fla­tion Re­duc­tion Act, CMS will

On­col­o­gists were more like­ly to pro­vide low-val­ue can­cer drugs to their pa­tients af­ter re­ceiv­ing per­son­al pay­ments from phar­ma com­pa­nies than those who did not re­ceive

As the FDA tight­ens its fo­cus on rare dis­ease treat­ments and speed­ing their en­try to mar­ket, law­mak­ers on Capi­tol Hill are putting se­ri­ous stock in

Na­tion­al Can­cer In­sti­tute di­rec­tor Mon­i­ca Bertag­nol­li re­ceived the Sen­ate health com­mit­tee’s stamp of ap­proval to helm the NIH — but as promised, Bernie Sanders strayed

Sen­ate Health Com­mit­tee Chair Bernie Sanders (I-VT) is call­ing on the HHS in­spec­tor gen­er­al to in­ves­ti­gate an NIH pro­pos­al to grant an ex­clu­sive patent li­cense

The FDA on Mon­day pub­lished an­oth­er draft guid­ance on drug com­pa­nies’ com­mu­ni­ca­tions with health­care providers re­gard­ing the un­ap­proved use of ap­proved med­ical prod­ucts. The 29-page

Re­pub­li­cans on the House En­er­gy and Com­merce Com­mit­tee are de­mand­ing that the NIH hand over more de­tails on its mpox re­search, ac­cord­ing to a let­ter